Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsLight the Night for Amyloidosis 2025February 20, 2025Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with PolyneuropathyAugust 24, 2022Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in AdultsJune 14, 2022 Previous postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosisNext post2026 Winter Newsletter